With $130M series B, Day One explores new pediatric cancer targets as it prepares for launch

A $130 million series B round led by RA Capital is enabling pediatric oncology company Day One to pursue new targets in spaces favored by investors, FDA and NCI — and prepare commercial infrastructure for lead candidate DAY101, which the company thinks could launch as early as 2023.

“Since the company has been established, there has been some greater refinement in understanding around specific target classes, and targets of interest,” CEO Jeremy Bender told BioCentury...